Vascular Biology |
From the Dipartimento di Fisiopatologia Clinica, Università di Torino (G.M., E.L., E.B., L.D.S., G.E.); the Ospedale Gradenigo (E.L.); and the Dipartimento di Medicina Interna, Università di Torino (M.B., L.B., G.C.), Torino, Italy.
Correspondence to Dr G. Camussi, Cattedra di Nefrologia, Dipartimento di Medicina Interna, Corso Dogliotti 14, 10126, Torino, Italy. E-mail giovanni.camussi{at}unito.it
AbstractWe previously reported that platelet-activating factor (PAF) enhances the angiogenic activity of certain polypeptide mediators such as tumor necrosis factor and hepatocyte growth factor by promoting endothelial cell motility. The purpose of the present study was to evaluate whether the synthesis of PAF induced by vascular endothelial growth factor (VEGF) might affect endothelial cell motility, microvascular permeability, and angiogenesis. The neoangiogenesis and synthesis of PAF induced by VEGF were studied in vivo in a murine Matrigel model. Dermal permeability was studied in mice by injection of 125I-albumin. The synthesis of PAF, cell motility, and the increased 125I-albumin transfer across endothelial monolayers were studied in vitro by using cultures of human umbilical cord veinderived endothelial cells (HUVECs). The results obtained demonstrate that the neoangiogenesis induced by VEGF in vivo was associated with a local synthesis of PAF and was inhibited by WEB2170 and CV3988, 2 chemically unrelated, specific PAF-receptor antagonists. In contrast, WEB2170 did not inhibit VEGF-enhanced dermal permeability, suggesting that the latter was independent of the synthesis of PAF. In vitro, it was found that VEGF induced the synthesis of PAF by HUVECs in a dose- and time-dependent manner. The cell motility induced by VEGF was inhibited by PAF-receptor antagonists. In contrast, VEGF-induced proliferation of HUVECs and albumin transfer through HUVEC monolayer were unaffected by PAF-receptor antagonists. These results suggest that the synthesis of PAF induced by VEGF enhances endothelial cell migration and contributes to the angiogenic effect of VEGF in the in vivo Matrigel model.
Key Words: vascular endothelial growth factor platelet-activating factor angiogenesis
This article has been cited by other articles:
![]() |
S. Doublier, M. Ceretto, E. Lupia, S. Bravo, B. Bussolati, and G. Camussi The Proangiogenic Phenotype of Tumor-Derived Endothelial Cells is Reverted by the Overexpression of Platelet-Activating Factor Acetylhydrolase Clin. Cancer Res., October 1, 2007; 13(19): 5710 - 5718. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Denizot, T. Chianea, F. Labrousse, V. Truffinet, M. Delage, and M. Mathonnet Platelet-activating factor and human thyroid cancer Eur. J. Endocrinol., July 1, 2005; 153(1): 31 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Russo, B. Bussolati, I. Deambrosis, F. Mariano, and G. Camussi Platelet-Activating Factor Mediates CD40-Dependent Angiogenesis and Endothelial-Smooth Muscle Cell Interaction J. Immunol., November 15, 2003; 171(10): 5489 - 5497. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Biancone, V. Cantaluppi, L. Del Sorbo, S. Russo, L. W. Tjoelker, and G. Camussi Platelet-activating Factor Inactivation by Local Expression of Platelet-activating Factor Acetyl-Hydrolase Modifies Tumor Vascularization and Growth Clin. Cancer Res., September 15, 2003; 9(11): 4214 - 4220. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bussolati, L. Biancone, P. Cassoni, S. Russo, M. Rola-Pleszczynski, G. Montrucchio, and G. Camussi PAF Produced by Human Breast Cancer Cells Promotes Migration and Proliferation of Tumor Cells and Neo-Angiogenesis Am. J. Pathol., November 1, 2000; 157(5): 1713 - 1725. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Montrucchio, G. Alloatti, and G. Camussi Role of Platelet-Activating Factor in Cardiovascular Pathophysiology Physiol Rev, October 1, 2000; 80(4): 1669 - 1699. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Hardy, I. Dumont, M. Bhattacharya, X. Hou, P. Lachapelle, D. R. Varma, and S. Chemtob Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy Cardiovasc Res, August 18, 2000; 47(3): 489 - 509. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |